These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36719280)

  • 81. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
    Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Impacts of clofazimine on the treatment outcomes of drug-resistant tuberculosis.
    Wang MG; Liu XM; Wu SQ; He JQ
    Microbes Infect; 2023; 25(1-2):105020. PubMed ID: 35792202
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    Lan Z; Ahmad N; Baghaei P; Barkane L; Benedetti A; Brode SK; Brust JCM; Campbell JR; Chang VWL; Falzon D; Guglielmetti L; Isaakidis P; Kempker RR; Kipiani M; Kuksa L; Lange C; Laniado-Laborín R; Nahid P; Rodrigues D; Singla R; Udwadia ZF; Menzies D;
    Lancet Respir Med; 2020 Apr; 8(4):383-394. PubMed ID: 32192585
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 86. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.
    Sonnenkalb L; Carter JJ; Spitaleri A; Iqbal Z; Hunt M; Malone KM; Utpatel C; Cirillo DM; Rodrigues C; Nilgiriwala KS; Fowler PW; Merker M; Niemann S;
    Lancet Microbe; 2023 May; 4(5):e358-e368. PubMed ID: 37003285
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 90. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
    Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
    Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
    Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C
    Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Decentralized, Integrated Treatment of RR/MDR-TB and HIV Using a Bedaquiline-Based, Short-Course Regimen Is Effective and Associated With Improved HIV Disease Control.
    Govender T; Jham MA; Zhang JC; Pillay S; Pak Y; Pillay P; Furin J; Malenfant J; Murphy RA
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):385-392. PubMed ID: 36729541
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Galesi VM; Barreira D; Sanchez DA; Dockhorn F; Centis R; Caminero JA; Migliori GB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331044
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes.
    Shiromwar SS; Khan AH; Chidrawar V
    Rev Esp Quimioter; 2023 Feb; 36(1):30-44. PubMed ID: 36503203
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2020 Dec; 111(1):61-67. PubMed ID: 33404008
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Improving access to contraception through integration of family planning services into a multidrug-resistant tuberculosis treatment programme.
    Cornish EF; Hudson J; Sayers R; Loveday M
    BMJ Sex Reprod Health; 2020 Apr; 46(2):152-155. PubMed ID: 31776175
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
    Olayanju O; Esmail A; Limberis J; Dheda K
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.